{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 04
 | day        = 17
 | notes      = ''{{USBill|113|S.|752}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Cody Miller Initiative for Safer Prescriptions Act ( S. 752; 113th Congress)
 | bill       = 752
 | billtype   = s
 | purpose    = To require the Secretary of Health and Human Services to promulgate regulations regarding the authorship, content, format, and dissemination of Patient Medication Information to ensure patients receive consistent and high-quality information about their prescription medications and are aware of the potential risks and benefits of prescription medications.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|1st Session}}

 
{{Center|S. 752}}

 
{{Center|IN THE SENATE OF THE UNITED STATES}}

  
{{Center|April 17, 2013}}

 
{{Center| 
[[w:|Mrs. Gillibrand]]introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor, and Pensions]] }}

  
{{Center|A BILL}}

 To require the Secretary of Health and Human Services to promulgate regulations regarding the authorship, content, format, and dissemination of Patient Medication Information to ensure patients receive consistent and high-quality information about their prescription medications and are aware of the potential risks and benefits of prescription medications.   

=Section 1. Short title=

This Act may be cited as the“ Cody Miller Initiative for Safer Prescriptions Act ”. 

=Sec. 2. Patient medication information for prescription drugs=

   Chapter V of the Federal Food, Drug, and Cosmetic Act ( [http://www.law.cornell.edu/uscode/text/21/351 21 U.S.C. 351 et seq.] )is amended by inserting after section 505E the following:

<blockquote> 

=Sec. 505F. Patient medication information for prescription drugs=



==(a) In general– ==

Not later than 2 years after the date of enactment of this section, the [[w:Department of Health and Human Services|Secretary]]shall issue regulations regarding the authorship, content, format, and dissemination requirements for patient medication information (referred to in this section as PMI ) for drugs subject to section 503(b)(1) .

==(b) Content– ==

The regulations promulgated under subsection (a) shall require that the PMI with respect to a drug—
:(1) be scientifically accurate and based on the professional labeling approved by the [[w:United States Department of Agriculture|Secretary]]and authoritative, peer-reviewed literature; and
:(2) includes nontechnical, understandable, plain language that is not promotional in tone or content, and contains at least—
::(A) the established name of drug, including the established name of such drug as a listed drug (as described in section 505(j)(2)(A) ) and as a drug that is the subject of an approved abbreviated new drug application under section 505(j) or of an approved license for a biological product submitted under section 351(k) of the Public Health Service Act , if applicable;
::(B) drug uses and clinical benefits;
::(C) general directions for proper use;
::(D) contraindications, common side effects, and most serious risks of the drug, especially with respect to certain groups such as children, pregnant women, and the elderly;
::(E) measures patients may be able to take, if any, to reduce the side effects and risks of the drug;
::(F) when a patient should contact his or her health care professional;
::(G) instructions not to share medications, and, if any exist, key storage requirements, and recommendations relating to proper disposal of any unused portion of the drug; and
::(H) known clinically important interactions with other drugs and substances.

==(c) Timeliness, consistency, and accuracy– ==

The regulations promulgated under subsection (a) shall include standards related to—
:(1) performing timely updates of drug information as new drugs and new information becomes available;
:(2) ensuring that common information is applied consistently and simultaneously across similar drug products and for drugs within classes of medications in order to avoid patient confusion and harm; and
:(3) developing a process, including consumer testing, to assess the quality and effectiveness of PMI in ensuring that PMI promotes patient understanding and safe and effective medication use.

==(d) Electronic repository– ==

The regulations promulgated under subsection (a) shall provide for the development of a publicly accessible electronic repository for all PMI documents and content to facilitate the availability of PMI. . 
</blockquote>
 

=Sec. 3. Publication on internet website=

The [[w:Department of Health and Human Services|Secretary of Health and Human Services]]shall publish on the Internet website of the [[w:Food and Drug Administration|Food and Drug Administration]]a link to the Daily Med website (http://dailymed.nlm.nih.gov/dailymed) (or any successor website).  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
